Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Operating Cash Flow

Cash generated by the company's core business operations during the period.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow turns positive

Q2 FY2026 operating cash flow was $23.33M, compared with -$47.05M a year earlier. Trailing-twelve-month operating cash flow was -$197.72M. Over 3 fiscal years it compounded at -5.5% a year.

Context

  • Operating cash flow amounted to 19.8% of revenue in FY2025, down 233.1 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly operating cash flow holds near $23.33M or moves back toward the trailing-twelve-month quarterly average of -$49.43M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$23.33M+113.9% QoQ
Last fiscal yearDec 2025
-$189.55M-58.4% YoY
LTMJun 2026
-$197.72M-35.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+149.6%——
1 year-58.4%——
3-year CAGR-5.5%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(189.55M) USD
Year-over-year change
+58.4%

Operating Cash Flow vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.7% is the 6th highest of 7, against a peer median of +2.6%.
  • Operating cash flow amounts to 15.4% of revenue for MDGL, versus a peer median of 2133.6%.
MDGL Competitors
Operating Cash Flow for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$418.44M USD+174.3%+79.2%—
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$197.72M USD-35.7%-5.5%15.4%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$143.46M USD+15.6%—2014.6%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$121.54M USD-273.9%+4.1%607.7%
IVAInventiva S.A.FY2025€100.98M EUR+17.5%+31.0%2252.6%
ALTAltimmune, Inc.LTM Mar 2026$71.94M USD-10.5%+2.6%199819.4%
SGMTSagimet Biosciences Inc.LTM Mar 2026$39.73M USD-21.7%+23.1%—
Peer median (excluding MDGL) —+2.6%+23.1%2133.6%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Depreciation & Amortization405K467K527K1.1M1.51M
Deferred Income Tax(7.32M)0000
Stock-Based Compensation26.87M31.63M49.74M79.88M98.13M
Change in Working Capital30.65M37.6M(3.28M)(72.35M)(8.5M)
Accounts Receivables000(53.82M)(80.65M)
Inventory000(34.07M)(36.98M)
Accounts Payables20.36M2.45M4.21M15.56M5.28M
Other Working Capital10.29M35.15M(7.49M)(13K)103.86M
Other Non-Cash Items7.32M797K2.41M1.69M7.59M
Operating Cash Flow(183.92M)(224.86M)(324.23M)(455.57M)(189.55M)
Capital Expenditures(209K)(217K)(1.48M)(1.46M)(467K)
Acquisitions (Net)787K(3K)000
Purchases of Investments(394.12M)(143.48M)(834.44M)(1.13B)(1.05B)
Sales of Investments389.27M350.38M333.4M839.19M1.09B
Other Investing Activities(787K)3K019.09M(8.97M)
Investing Cash Flow(5.06M)206.69M(502.52M)(274.39M)32.32M
Debt Repayment050M65M0217.93M
Common Stock Issued170.21M255.38M260.19M397.49M38.06M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.03M8.07M269.93M337.58M0
Financing Cash Flow171.24M313.45M595.12M735.06M255.98M
Effect of Forex Changes000013K
Net Change in Cash(17.74M)295.28M(231.63M)5.1M98.76M
Free Cash Flow(184.13M)(225.07M)(325.71M)(457.03M)(190.02M)

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.